-
公开(公告)号:US12122828B2
公开(公告)日:2024-10-22
申请号:US18460944
申请日:2023-09-05
发明人: Gerben Bouma , Edward Thomas Coulstock , David Dixon , Stephanie Hopley , Alan Peter Lewis , Jessica Lynn Neisen
CPC分类号: C07K16/244 , A61K2039/505 , C07K2317/92 , C07K2317/94
摘要: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.
-
公开(公告)号:US12043436B2
公开(公告)日:2024-07-23
申请号:US17896538
申请日:2022-08-26
发明人: Francesco Sanmartin
CPC分类号: B65B59/04 , A61L2/04 , B65B3/003 , B65B7/2821 , B65B43/42 , B65B55/025 , A61L2202/21
摘要: A modular production system including a plurality of production modules connected in a linear series to form a production tunnel, and collectively defining a production channel, and wherein at least one fluid inlet port defined along the production tunnel, said inlet port is in fluid communication with a pressurized fluid source, whereby influx of fluid from said fluid source through said fluid inlet port acts to maintain the fluid pressure within the production channel at a higher pressure than the atmospheric pressure outside of the production tunnel; and wherein one of said production modules positioned between said proximal-most and distal-most production modules comprises a depyrogenator and/or sterilization module, comprising a transparent tubular body, and an irradiation source positioned external to said transparent tubular body, said irradiation source capable of heating the internal environment of the depyrogenation and/or sterilization module to a temperature sufficient to depyrogenate or sterilize articles passing therethrough, and associated processes.
-
公开(公告)号:US20240180933A1
公开(公告)日:2024-06-06
申请号:US18358998
申请日:2023-07-26
IPC分类号: A61K31/675 , A61K31/44 , A61P35/02 , C07D213/85 , C07F9/58
CPC分类号: A61K31/675 , A61K31/44 , A61P35/02 , C07D213/85 , C07F9/58 , C07B2200/13
摘要: The invention relates to substituted pyridine derivatives that are inhibitors of the activity of DNA methyltransferase 1 (DNMT1). The invention also relates to pharmaceutical compositions comprising such compounds and methods of using such compounds in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity.
-
公开(公告)号:US11976113B2
公开(公告)日:2024-05-07
申请号:US16988257
申请日:2020-08-07
发明人: Steven Grant , Martin Orecchia , Chika Akinseye , Laura Hook , Alan Lewis , Tejinder Bhinder
IPC分类号: C07K16/24 , A61K39/395 , A61K39/00
CPC分类号: C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/524 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/72 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94
摘要: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
-
公开(公告)号:US11970480B2
公开(公告)日:2024-04-30
申请号:US17663749
申请日:2022-05-17
发明人: Adam Kenneth Charnley , Michael G. Darcy , Jason W. Dodson , Xiaoyang Dong , Terry V. Hughes , Jianxing Kang , Lara Kathryn Leister , Yiqian Lian , Yue Li , John F. Mehlmann , Neysa Nevins , Joshi M. Ramanjulu , Joseph J. Romano , Gren Z. Wang , Guosen Ye , Daohua Zhang
IPC分类号: C07D403/14 , C07D405/14 , C07D413/14 , C07D487/22 , C07D493/10 , C07D498/18 , C07F9/6558
CPC分类号: C07D403/14 , C07D405/14 , C07D413/14 , C07D487/22 , C07D493/10 , C07D498/18 , C07F9/65583
摘要: Disclosed are compounds having the formula:
wherein q, r, s, A, B, C, RA1, RA2, RB1, RB2, RC1, RC2, R3, R4, R5, R6, R14, R15, R16, and R17, are as defined herein, or a tautomer thereof, or a salt, particularly a pharmaceutically acceptable salt, thereof.-
公开(公告)号:US11945826B2
公开(公告)日:2024-04-02
申请号:US17429088
申请日:2020-02-11
发明人: Mark Elban , Michal Pawel Glogowski , Michael Clinton Koetting , Brian Griffin Lawhorn , Jay M. Matthews , Jaclyn Renee Patterson
IPC分类号: C07D498/04 , C07D498/10
CPC分类号: C07D498/04 , C07D498/10 , C07B2200/13
摘要: The present invention relates hydroxypyridoxazepine compounds, methods of making them, pharmaceutical compositions containing them and their use as Nrf2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, or a tautomer thereof, or a hydrate thereof.
-
公开(公告)号:US20240051972A1
公开(公告)日:2024-02-15
申请号:US17899877
申请日:2022-08-31
申请人: GlaxoSmithKline Intellectual Property Development Limited , The University of North Carolina at Chapel Hill , ViiV Healthcare Company
IPC分类号: C07D519/00 , A61P31/18
CPC分类号: C07D519/00 , A61P31/18
摘要: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.
-
公开(公告)号:US11795474B2
公开(公告)日:2023-10-24
申请号:US16606281
申请日:2018-04-18
发明人: Conrad Vink
CPC分类号: C12N15/86 , C07K14/161 , C07K14/162 , C12N2740/13052 , C12N2740/15052 , C12N2740/16052 , C12N2799/027 , C12N2830/003 , C12N2830/006 , C12N2830/60
摘要: The invention relates to retroviral producer cell comprising nucleic acid sequences encoding: gag and pol proteins; envelope protein or a functional substitute thereof; amplifiable selection marker; and the RNA genome of the retroviral vector particle, wherein said nucleic acid sequences are all integrated at a single locus within the retroviral producer cell genome. The invention also relates to nucleic acid vectors comprising a non-mammalian origin of replication and the ability to hold at least 25 kilobases (kb) of DNA, characterized in that said nucleic acid vector comprises retroviral nucleic acid sequences encoding: gag and pol proteins, and an env protein or a functional substitute thereof. The nucleic acid vector additionally comprises nucleic acid sequences encoding an amplifiable selection marker. The invention also relates to uses and methods using said nucleic acid vector in order to produce stable retroviral packaging and producer cell lines.
-
公开(公告)号:US11643407B2
公开(公告)日:2023-05-09
申请号:US17056495
申请日:2019-05-16
发明人: Jeffrey K. Kerns
IPC分类号: C07D417/10 , C07D249/04 , A61K9/00
CPC分类号: C07D417/10 , C07D249/04 , A61K9/0019 , A61K9/0053
摘要: The present invention relates to indane compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I) or Formula (II), and pharmaceutically acceptable salts thereof:
-
公开(公告)号:US20230131598A1
公开(公告)日:2023-04-27
申请号:US17911816
申请日:2021-04-12
摘要: The invention relates to a method of treating cancer, such as head and neck cancer (e.g. head and neck squamous cell carcinoma and oropharyngeal cancer), lung cancer (e.g. non small cell lung cancer), urothelial cancer, melanoma or cervical cancer, involving the combination of an ICOS binding protein (e.g. an anti-ICOS antibody) and a TIM-3 binding protein (e.g. an anti-TIM-3 antibody) and, optionally, a PD-1 binding protein (e.g. an anti-PD-1 antibody).
-
-
-
-
-
-
-
-
-